Skin cancers under Janus kinase inhibitors: A World Health Organization drug safety database analysis
Cédric Jalles, Marion Lepelley, Stéphane Mouret, J. Charles, M.‐T. Leccia, Sabiha Trabelsi
Topics & Concepts
RuxolitinibMedicineTofacitinibJanus kinase inhibitorSkin cancerJanus kinaseOncologyPharmacovigilanceCancerInternal medicineIpilimumabPopulationMerkel cell carcinomaDermatologyCancer researchCarcinomaAdverse effectMyelofibrosisBone marrowRheumatoid arthritisImmunotherapyEnvironmental healthCytokineMyeloproliferative Neoplasms: Diagnosis and TreatmentCytokine Signaling Pathways and InteractionsPolyomavirus and related diseases